Jingtai Technology (02228.HK) helps Zhijing Biotechnology's new generation of "synthetic lethality" new drug to obtain clinical trial approval, AI pharmaceuticals welcome another milestone.

According to the Zhidao Finance APP, Crystal Tai Technology (02228.HK) announced today that the new generation PRMT5 inhibitor PEP08 discovered by PharmaEngine, Inc., with its assistance, has reached an important clinical development milestone. PEP08 has recently received clinical trial approvals from the Human Research Ethics Committee (HREC) of Australia, the Therapeutic Goods Administration (TGA) of Australia, and the Taiwan Food and Drug Administration (TFDA), indicating that the drug is about to initiate a Phase I clinical trial. Based on this progress, Crystal Tai Technology has confirmed receipt of milestone payments for this project.